A Russian original medication called Polyoxidonium® by Petrovax, a pharmaceutical company affiliated to the Interros Group, has passed the first phase of an international clinical trial for its effectiveness and safety for COVID-19 treatment.

Polyoxidonium (azoximer bromide) - the Russian original drug produced by Petrovax-  was approved by the Ministry of Health of the Russian Federation for conducting an international clinical trial for the treatment of COVID-19.

In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.